Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint

by Raffaella Ravinetto, Anja De Weggheleire, Thomas P.C. Dorlo et al.
Tropical Medicine and International Health, Vol. 21, No 12, pp 1490–1495, December 2016

6 pp. 83 kB
http://onlinelibrary.wiley.com/doi/10.1111/tmi.12784/epdfcover

New interferon-free direct-acting antiviral (DAA) treatment combinations have transformed the hepatitis C virus (HCV) treatment options with their potential to cure patients and stop the pandemic. However, the high prices set by innovator manufacturers keep these novel medicines out of reach of most patients in low- and middle-income countries (LMICs). The access strategies voluntarily put in place for LMICs by some pharmaceutical companies, although laudable, appear insufficient to achieve the goal of universal access. There is broad consensus among stakeholders that competition among quality-assured generics is now urgently needed to enable the launch of large-scale public treatment programmes and to change HCV treatment patterns worldwide.

(Visited 14 times, 1 visits today)
This entry was posted in Essential Medicines, Other Infectious Diseases. Bookmark the permalink.